Keytruda Patent Status and Expiry Timeline
Keytruda (pembrolizumab), Merck's blockbuster cancer immunotherapy, remains under patent protection in the US until at least 2028, with key composition-of-matter patents expiring around then and others extending to 2035 via pediatric exclusivity or method-of-use claims.[1] No expiry has occurred yet, so current pricing reflects monopoly conditions. Post-expiry, costs will drop sharply due to generic or biosimilar entry, but exact figures depend on market dynamics.
Current Keytruda Pricing Before Any Expiry
A single 100mg/4mL vial lists at about $11,500 in the US, with a 28-day cycle often costing $20,000-$30,000 depending on dose (typically 200mg or 400mg).[2] Annual treatment exceeds $150,000 for many patients. Prices vary globally: lower in Europe (e.g., €3,500-€4,000 per vial) and even less in markets like India via voluntary licensing.
Expected Price Drop After Patent Expiry
Once patents lapse around 2028-2035, biosimilars (not small-molecule generics) will enter, slashing costs by 30-80% based on precedents like Humira (adalimumab), where US biosimilars launched at 85% discounts.[3] Analysts project Keytruda biosimilars could price at $3,000-$8,000 per vial initially, with further declines to $1,000-$2,000 as competition grows. In Europe, where some patents expired earlier, biosimilars already trade at 25-40% of originator prices.
| Scenario | Projected US Vial Cost (100mg) | Timeline |
|----------|-------------------------------|----------|
| Initial biosimilar entry | $4,000-$7,000 | 2028+ |
| Mature competition (3+ biosimilars) | $1,500-$3,000 | 2030+ |
| Global low-income markets | $500-$1,000 | Immediate post-entry |
Factors Driving Post-Expiry Costs
- Biosimilar Makers: Amgen, Samsung Bioepis, and Organon plan US launches post-2028; more (e.g., Sandoz, Celltrion) target Europe sooner.[1]
- Regulatory Hurdles: FDA approval requires demonstrating similarity; first interchangeable biosimilars get 180-day exclusivity.
- PBM and Insurance Impact: US pharmacy benefit managers negotiate rebates, potentially keeping net prices higher than list despite drops.
- Litigation Risks: Merck sues challengers (e.g., ongoing vs. Viatris), possibly delaying entry 1-2 years.[1]
How Keytruda Compares to Similar Drugs Post-Expiry
Post-patent drugs like Rituxan (rituximab) fell 50-70% within years of biosimilar entry. Opdivo (nivolumab), a competitor, faces expiry around 2030-2033 with similar projected drops.[4] Patient assistance programs will likely persist, covering copays until prices normalize.
Access Options Before Expiry
Compassionate use, patient assistance (Merck covers ~10% of US patients), or imports from lower-price countries offer interim relief, but legality varies.[2]
[1]: DrugPatentWatch.com - Keytruda Patents
[2]: GoodRx - Keytruda Pricing
[3]: IQVIA Institute - Biosimilar Savings Report
[4]: DrugPatentWatch.com - Opdivo Patents